The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $133.29

Today's change0.00 0.00%
Updated September 2 4:06 PM EDT. Delayed by at least 15 minutes.
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $133.29

Today's change0.00 0.00%
Updated September 2 4:06 PM EDT. Delayed by at least 15 minutes.

Taro Pharmaceutical Industries Ltd closed at (U.S.)$133.29.

Over the last five days, shares have gained 0.83%, but are down 10.05% for the last year to date. Shares have underperformed the S&P 500 by 13.90% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $133.29
  • High--
  • Low--
  • Bid / Ask-- / --
  • YTD % change-10.05%
  • Volume0
  • Average volume (10-day)68,353
  • Average volume (1-month)76,632
  • Average volume (3-month)67,007
  • 52-week range(U.S.) $124.35 to (U.S.) $173.00
  • Beta0.80
  • Trailing P/E11.20×
  • P/E 1 year forward11.45×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $11.90
Updated September 2 4:06 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+56.27%

Based on its net profit margin of 56.27%, Taro Pharmaceutical Industries Ltd is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.47%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue244238251130
Total other revenue--------
Total revenue244238251130
Gross profit20019319885
Total cost of revenue45445345
Total operating expense91789176
Selling / general / administrative22212222
Research & development24131415
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)002-7
Other operating expenses, total--------
Operating income15415916054
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax19017117051
Income after tax15314314446
Income tax, total3728265
Net income15214214346
Total adjustments to net income--------
Net income before extra. items15314314446
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items15314314446
Inc. avail. to common incl. extra. items15214214346
Diluted net income15214214346
Dilution adjustment--------
Diluted weighted average shares37434343
Diluted EPS excluding extraordinary itemsvalue per share4.143.333.351.08
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share4.143.333.400.94